Quantcast
Last updated on April 19, 2014 at 13:20 EDT

New Oral Anticoagulants Markets

June 27, 2013

Rockville, MD | 6/26/2013 | PRWeb – MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: New Oral Anticoagulants Markets
http://www.marketresearch.com/land/product.asp?productid=7458266&progid=85535

(PRWEB) June 26, 2013

New Oral Anticoagulants Markets

TriMarkPublications.com cites in its newly published “New Oral Anticoagulants Markets” report that the global anticoagulants market will spike to over $24 billion by 2019.

Anticoagulants decrease the ability of the blood to create harmful blood clots that can ultimately lead to a heart attack or stroke. Although sometimes referred to as blood thinners, they do not actually thin the blood and only help prevent the formation of new blood clots.

Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and other new oral anticoagulants have several advantages over warfarin, including no periodical laboratory monitoring and more predictable effects with fixed doses.

The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $7.06 billion in 2012 to $15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.

”New Oral Anticoagulants Markets” provides a thorough overview of these and other new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and the respective areas of market growth.

The report also examines companies manufacturing anticoagulant equipment and supplies in the world. Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi. Detailed charts with sales forecasts and marketshare data are included.

New Oral Anticoagulants Markets – Table of Contents:

1. Introduction

1.1 Scope of this Report

1.2 Methodology

1.3 Executive Summary

2. An Overview of Anticoagulants

2.1 Scope of this Chapter

2.1.1 Unmet Medical Needs with Existing Anticoagulants

2.1.2 Pharmacology of Injectable Anticoagulants

2.1.3 Marketed and Registered Drugs for Anticoagulation and Related Disorders

2.2 Oral Anticoagulants

2.2.1 Potential Limitations of New Oral Anticoagulants

2.2.2 Desired Attributes of Anticoagulants

2.2.3 Comparison of New Anticoagulants

2.2.4 Bleed Rates of New Anticoagulants

3. Selected Oral Anticoagulants

3.1 Warfarin

3.1.1 Warfarin’s Place in Clinical Therapy

3.1.2 Drug Interaction with Warfarin

3.1.3 Warfarin’s Interactions with Food

3.1.4 Interactions of Warfarin with Dietary Vitamin K

3.2 Dabigatran (Pradaxa)

3.2.1 Use of Dabigatran in Particular Situations

3.2.2 Measuring the Anticoagulant Effect of Dabigatran

3.2.3 Activated Partial Thromboplastin Time (aPTT)

3.2.4 Thrombin Time (TT) and Hemoclot

3.2.5 Ecarin Clotting Time (ECT)

3.2.6 Prothrombin Time (PT) and INR

3.2.7 Measures for Overdose

3.2.8 Management of Bleeding Complications

3.2.9 For Patients Undergoing Surgical Intervention

3.2.10 For Dental Interventions

3.2.11 For Spinal Anesthesia/Epidural Anesthesia/Lumbar Puncture

3.2.12 For Patients with Acute Coronary Syndrome (ACS)

3.2.13 Cardioversion in Dabigatran Treated Patients

3.2.14 For Patients with Stroke

3.2.15 Dabigatran after Ischemic Stroke

3.2.16 Strengths and Weaknesses of Dabigatran

3.2.16.1 Strengths of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics

3.2.16.2 Weaknesses of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics

3.2.16.3 Strengths of Dabigatran in Laboratory Monitoring

3.2.16.4 Weaknesses of Dabigatran in Laboratory Monitoring

3.2.16.5 Strengths of Dabigatran in Clinical Efficacy

3.2.16.6 Weaknesses of Dabigatran in Clinical Efficacy

3.2.16.7 Strengths of Dabigatran in Controlling Bleeding

3.2.17 Comparison of Dabigatran and Rivaroxaban in Sites of Action

3.3 Rivaroxaban (Xarelto)

3.3.1 Dosage and Administration

3.3.2 Risk of Stroke after Discontinuation in Non-Valvular Atrial Fibrillation

3.3.3 Risk of Bleeding

3.3.4 Bleeding Events in ROCKET AF Trial

3.3.5 Bleeding Events in RECORD Trial

3.3.6 Overdosage

3.3.7 Mechanism of Action

3.3.8 Comparable Efficacy of Rivaroxaban

3.3.9 Prophylaxis of Deep Vein Thrombosis

3.4 Eliquis (Apixaban)

3.4.1 AVERROES Results

3.5 Edoxaban

3.6 Betrixaban

3.7 Pipeline Agents

3.8 Comparison of Oral Anticoagulants

3.9 Heparins

3.10 Dalteparin (Fragmin)

3.11 Enoxaparin (Lovenox)

3.11.1 Indications and Usage

3.11.2 Percutaneous Coronary Revascularization Procedures

3.11.3 Use of Lovenox with Concomitant Medical Conditions

3.11.3.1 Thrombocytopenia

3.11.3.2 Interchangeability with Other Heparins

3.11.3.3 Pregnant Women with Mechanical Prosthetic Heart Valves

3.11.3.4 Laboratory Tests

3.11.3.5 Pharmacodynamics

3.11.3.6 Pharmacokinetics

3.12 Fondaparinux (Arixtra)

3.13 Tinzaparin (Innohep)

3.14 Semuloparin Sodium (AVE5026)

3.15 Idrabiotaparinux

3.16 Otamixaban

3.17 RB006

3.18 Reversal Agents and Antidotes

3.18.1 Vitamin K

3.18.2 Recombinant Factor VIIa

3.18.3 Prothrombin Complex Concentrates

4. A Brief Overview of Antiplatelets

4.1 Overview of this Chapter

4.1.1 Differences between Antiplatelets and Anticoagulants

4.1.2 Need for Antiplatelets

4.1.3 Side Effects of Antiplatelets

4.1.4 Choosing an Antiplatelet

4.1.5 Role of Platelets in Thrombosis

4.1.6 Inhibitors of Platelet Adhesion

4.1.7 Inhibitors of Platelet Activation

4.1.7.1 Inhibitors of TXA2 Pathway

4.1.7.2 Inhibitors of P2Y12

4.1.7.3 PAR-1 Inhibitors

4.1.7.4 Phosphodiesterase Inhibitors

4.2 Antiplatelet Drugs

4.2.1 Aspirin

4.2.2 Aggrenox

4.2.3 Ticagrelor (Brilinta)

4.2.4 Clopidogrel (Plavix)

4.2.4.1 Indications and Usage

4.2.4.2 General Risk of Bleeding

4.2.5 Effient (Prasugrel)

5. Coagulation Assays

5.1 Clotting Assays

5.1.1 Chromogenic Methods

5.1.2 Prothrombin Time

5.1.3 Activated Partial Thromboplastin Time

5.1.4 Thrombin Time

5.1.5 Fibrinogen (Clauss Method)

5.1.6 Derived Fibrinogen

5.1.7 Antithrombin

5.1.8 Protein C

5.1.9 Protein S

5.1.10 Lupus Anticoagulants

5.1.11 ProC Global Assay and APC Resistance (APCR)

5.2 Influence of New Anticoagulants on Coagulation Assays

6. Disease Conditions Targeted by Anticoagulants

6.1 Cardiovascular Diseases

6.1.1 Stroke

6.1.2 Ischemic Stroke

6.1.3 Hemorragic Stroke

6.1.4 Subarachnoid Hemorrage

6.1.5 Global Incidence and Prevalence of Stroke

6.1.6 Incidence of Stroke in the U.S.

6.1.7 Mortality from Heart Disease and Stroke in Selected OECD Countries

6.1.8 Anticoagulants Used in the Treatment for Stroke

6.1.8.1 Heparin

6.1.8.2 Warfarin

6.1.9 Antiplatelets

6.1.9.1 Aspirin

6.1.9.2 Dipyridamole

6.1.9.3 Clopidogrel

6.1.10 Transient Ischemic Attack (Mini Stroke)

6.1.10.1 Drug Therapy for Mini Stroke

6.1.11 Market for Stroke Medication

6.2 Cardiac Arrhythmia

6.2.1 Tachycardias

6.2.2 Bradycardias

6.2.3 Medications for Arrhythmias

6.2.4 Anticoagulants Used to Treat Arrhythmias

6.2.5 Global Market for Atrial Fibrillation Drugs

6.2.6 Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

6.2.7 Clinical Data on Direct Thrombin Inhibitors

6.2.7.1 Dabigatran

6.2.7.2 Clinical Data on Oral Factor Xa Inhibitors

6.2.8 Rivaroxaban

6.2.9 Apixaban

6.2.10 Betrixaban

6.2.11 Edoxaban

6.3 Coronary Artery Disease

6.3.1 Global CAD Therapeutics Market

6.3.2 Anticoagulation in Acute Coronary Syndrome

6.3.3 Antiplatelet Therapy

6.3.4 Antricoagulants Therapy

6.4 Heart Attack (Myocardial Infarction)

6.4.1 Global Market for CHF Pharmaceuticals

6.4.2 Declining Trend in the U.S. Heart Attack Rates

6.4.3 Cost of Cardiovascular Diseases

6.5 Heart Valve Replacement

6.5.1 Market Trends in Prosthetic Heart Valves

6.5.2 Market for Mechanical Heart Valves

6.5.3 Market for Tissue Heart Valves

6.5.4 Heart Valve Replacement and Anticoagulants

6.5.4.1 Anticoagulation Therapy in Patients with Prosthetic Heart Valves

6.6 Deep Vein Thrombosis (DVT)

6.6.1 Commonly Recognized Signs and Symptoms of DVT

6.6.2 Complications of VTE

6.6.3 Use of Risk Assessment Tools in the Diagnosis of DVT

6.6.4 Current Anticoagulants Treatment Modalities for DVT

6.6.5 Use of Xarelto

6.6.6 Use of Enoxaparin: Inpatient and Outpatient

6.6.7 Use of Fondaparinux: Inpatient

6.6.8 Prophylactic Interventions

6.7 Joint Replacement Surgery and Risk of Blood Clot Formation

6.7.1 Joint Replacement Surgeries in the U.S.

6.7.2 Hip and Knee Replacement Surgeries in OECD Countries

6.7.3 Global Orthopedic Industry

6.7.4 Hip Replacement

6.7.4.1 U.S. Market for Hip Replacement

6.7.5 Knee Replacement

6.7.5.1 U.S. Knee Replacement Market

6.7.6 Shoulder Replacement

6.7.6.1 Global Shoulder Replacement Market

6.7.7 Oral Thrombophylaxis Following Total Hip and Knee Replacement

6.7.7.1 Thrombophylactic Agents

6.7.7.2 Reasons for Increased Clot Risk after Surgery

6.8 Prophylactic Anticoagulation after a Hip Fracture

6.8.1 Pharmacologic Prevention of Blood Clots after a Hip Fracture

6.8.1.1 Aspirin

6.8.1.2 Warfarin

6.8.1.3 Heparins

6.8.1.4 Fondaparinux

6.8.2 Duration of Prophylaxis after Hip Fracture

6.9 Pulmonary Embolism (Blood Clot in the Lung)

6.9.1 Signs and Symptoms of Pulmonary Embolism

6.9.2 Anticoagulation Therapy for Pulmonary Embolism

6.10 Oral Surgery and Anticoagulation Therapy

6.10.1 Required Laboratory Investigations for Dental Patients on Anticoagulation

6.11 Hemodialysis

6.11.1 Global Market for Hemodialysis

6.11.2 Global Operators of Dialysis Clinics

6.11.3 Global Leaders in Hemodialysis Products

6.11.4 Global Leaders in Peritoneal Dialysis Products

6.11.5 Anticoagulation in Hemodialysis

6.12 Cancer

6.12.1 Global Market for Cancer Therapeutics

6.12.2 The Cancer-Thrombosis Connection

7. Market Analysis: Anticoagulants

7.1 Overview of this Chapter

7.2 Oral Anticoagulants

7.2.1 Vitamin K Antagonists

7.2.1.1 Global Market for Warfarin

7.2.1.2 The Threatened Position of Warfarin in the Anticoagulants Market

7.2.1.3 Newer Oral Anticoagulants to Replace Warfarin

7.2.1.4 Potential Alternatives to Warfarin

7.2.2 Factor Xa Inhibitors

7.2.2.1 Global Market for Factor Xa Inhibitors

7.2.3 Global Market for Xarelto (Rivaroxaban)

7.2.3.1 Xarelto: A Great Promise

7.2.3.2 U.S. Market for Xarelto

7.2.3.3 U.S. Market Share for Eliquis, Xarelto and Pradaxa

7.2.4 Direct Thrombin Inhibitors (DTI)

7.2.4.1 Global Market for Direct Thrombin Inhibitors

7.2.5 Global Market for Pradaxa (Dabigatran)

7.2.5.1 Dawning of the Age of Dabigatran

7.2.5.2 Pradaxa: Bringing Potential Sea Change in AF

7.2.5.3 Dabigatran’s First Year in the Market

7.3 Parenteral Anticoagulants

7.3.1 Pharmacology of Parenteral Anticoagulants

7.3.2 Adverse Effects of Parenteral Anticoagulants

7.3.3 Parenteral Thrombin Inhibitors

7.3.3.1 Parenteral Indirect Thrombin Inhibitors

7.3.3.2 Market for Unfractionated Heparin (UFH)

7.3.3.3 Market for Low Molecular Weight Heparin (LMWH)

7.3.3.4 Distribution of LMWH Sales per Indication

7.3.4 Global Market for Lovenox

7.3.4.1 Lovenox: The Broadest Label

7.3.5 Pentasaccharide Anticogulants

7.3.5.1 Fondaparinux (Arixtra)

7.3.5.2 Arixtra: A Missed Opportunity

7.3.6 Parenteral Direct Thrombin Inhibitors

7.3.6.1 Bivalirudin (Angiomax)

7.4 Market for Venous Thromboembolic Drugs

7.5 Market for Direct Thrombin Inhibitors

7.6 Comparisons of Market Opportunities for Anti-Thrombotic Agents

7.7 Global Market for Anticoagulants

7.7.1 Market Share of Anticoagulants by Type

7.8 U.S. Market for Anticoagulants

7.9 More Anticoagulants in Pipeline

8. Market for Antiplatelets

8.1 Overview of this Chapter

8.2 The Threatened Market of Plavix

8.2.1 Patent Loss of Plavix

8.2.2 Patent Loss of Plavix and Competitive Advantages for New Entrants

8.3 Market for Effient (Prasugrel)

8.3.1 Slow Uptake of Effient

8.4 Market for Pletal (Cilostazol)

8.5 Market for Activase (Alteplase)

8.6 Market for Aggrenox

8.7 Market for CardioAspirin

8.8 Market for Opalmon

8.9 Market for Integrilin (Eptifibatide)

8.10 Market for ReoPro (Abciximab)

8.11 Market for Brilinta

8.12 Market for Diagnostic Assays of Platelet Function

8.13 The Anti-Platelet Pipeline

9. Deals in Anti-Thrombotic Therapeutics Sector

9.1 Sanofi’s Extensive Anti-Thrombotic Partnering Landscape

9.2 Daiichi Sankyo’s Licensing Portfolio

9.3 Merck & Co. Agreements for Arterial Thrombotic Therapeutics

9.4 Deals between Bristol-Myer’s Squibb and Pfizer

9.5 Partnership between Ortho-McNeil and Bayer for Xarelto

10. Utilization of Anticoagulants and Antiplatelets in the U.S.

10.1 Anti-Thrombotic Drugs Used in Asia-Pacific Countries

10.2 Antiplatelets Used in Asia-Pacific for Stroke Prevention

10.3 Antithrombotic Strategy According to CHADS2

10.4 Antithrombotic Strategy for Patients with No Risk Factors (CHADS2=0)

10.5 Antithrombotic Strategy for Patients with 1 Risk Factor (CHADS2=1)

10.6 Antithrombotic Strategy for Patients with (CHADS2=2) Score 2

10.7 Adjustment of INR According to Age

10.8 Antithrombotic Treatment for Paroxysmal vs. Persistent AF

10.9 Oral Anticoagulation during Tooth Extraction

10.10 Oral Anticoagulation during Endoscopy or General Surgery

10.11 Oral Anticoagulation during Cardioversion for Persistent AF and Paroxysmal AF

10.12 Awareness Levels about New Anticoagulants

10.13 Reasons for Prescribing Dabigatran

11. Selected Company Profiles

11.1 Akers Biosciences, Inc.

11.1.1 PIFA Heparin/Platelet Factor 4 Rapid Assay

11.2 Anthera Pharmaceuticals, Inc.

11.2.1 Varespladib/A-002

11.3 ARYx Therapeutics, Inc.

11.3.1 Tecarfarin

11.3.2 Tecarfarin Development Status

11.4 AstraZeneca, PLC

11.4.1 Brilinta (Ticagrelor)

11.5 Boehringer Ingelheim GmbH

11.5.1 Boehringer’s Dedication to Innovation

11.5.2 Boehringer’s Therapeutic Breakthrough

11.5.3 Registration Study RE-LY

11.6 Cipla Limited

11.7 Daiichi Sankyo Company Ltd.

11.7.1 LIXIANA

11.8 Eisai Co., Ltd.

11.8.1 Fragmin

11.9 Eli Lilly & Co

11.9.1 Effient (Daiichi Sankyo)

11.9.2 General Risk of Bleeding

11.9.3 Coronary Artery By-Pass Graft Surgery-Related Bleeding

11.9.4 Discontinuation of Effient

11.9.5 Thrombotic Thrombocytopenic Purpura

11.9.6 Hypersensitivity Including Angiodema

11.9.7 Clinical Studies

11.10 Genentech, Inc.

11.10.1 Activase (Altepase)

11.11 GlaxoSmithKline PLC

11.11.1 Fondaparinux

11.12 Medicure, Inc.

11.12.1 Aggrastat

11.13 Merck & Co., Inc.

11.13.1 SCH 5303348

11.14 Novartis AG

11.14.1 Elinogrel

11.15 Ortho-McNeil Pharmaceutical, Inc.

11.15.1 Rivaroxaban (Xarelto)

11.16 Pfizer, Inc.

11.16.1 Eliquis (Apixaban)

11.17 Pharmion, LLC

11.17.1 Tinzaparin (Innohep)

11.18 Portola Pharmaceuticals, Inc.

11.19 Sanofi

11.19.1 Lovenox (Enoxaparin)

11.19.2 Idrabiotaparinux

11.20 The Medicines Company

11.20.1 Argatroban

11.20.2 Angiomax (Bivalirudin)

Appendix 1: Innovations in Cardiac Rhythm Management with New Anticoagulants

Appendix 1.1: Dual Antiplatelet Therapy

Appendix 1.2: Direct Thrombin Inhibitors

Appendix 1.3: Factor Xa Inhibitors

Appendix 1.4: Comparing the Trials

Appendix 1.5: Interventions Targeting the Left Atrial Appendage

Appendix 2: Oral Contraceptives and the Risk of Venous Thromboembolism

Appendix 2.1: Hormonal Effects on Venus Thromboembolism

Appendix 2.2: Assessing Venous Thromboembolism Risks of Oral Contraceptives

Appendix 2.3: Recent Research

INDEX OF FIGURES

Figure 2.1: Almost 100 Years of Anticoagulation Therapy

Figure 2.2: Site of Action of New Anticoagulants

Figure 3.1: Pathway of Dabigatran Action

Figure 3.2: Sites of Action of Dabigatran and Rivaroxaban

Figure 3.3: Time to First Occurrence of Stroke by Treatment Group

Figure 3.4: Apixaban in Patients with Atrial Fibrillation

Figure 3.5: Management of Bleeding Complications (For all Oral Anticoagulants)

Figure 3.6: Blood Coagulation System Context for Heparin Anticoagulant Action

Figure 4.1: Role of Platelets in Thrombosis

Figure 4.2: Sites of Actions of Antiplatelets

Figure 6.1: Global Incidence and Prevalence of Stroke

Figure 6.2: U.S. Hospitalization Rates for Stroke for those Aged 65 and Over, 1989-2009

Figure 6.3: Mortality Rates for Ischemic Heart Disease in Selected OECD Countries, 2009

Figure 6.4: Global Market for Stroke Medications, 2012-2019

Figure 6.5: Global Market for Atrial Fibrillation Drugs, 2012-2019

Figure 6.6: Coagulation Cascade

Figure 6.7: Cumulative Hazard Rates for the Primary Endpoint in the RE-LY Trial

Figure 6.8: Percentage of Cumulative Hazard Rates for the Primary Endpoint in the RE-LY Trial

Figure 6.9: All-Cause Mortality in the RE-LY Trial

Figure 6.10: Global CAD Therapeutics Market, 2012-2019

Figure 6.11: Management of UA/NSTEMI

Figure 6.12: Global Market for CHF Pharmaceuticals, 2012-2019

Figure 6.13: Global Market for Prosthetic Heart Valves, 2012-2019

Figure 6.14: Global Market for Mechanical Heart Valves, 2012-2019

Figure 6.15: Global Market for Tissue Heart Valves, 2012-2019

Figure 6.16: Recommendations from the Seventh ACCP Consensus Conference

Figure 6.17: Algorithm for Antithrombotic Therapy for Prosthetic Heart Valves

Figure 6.18: Phases of VT and Conventional Treatments with Anticoagulants

Figure 6.19: Estimated Increase of THR and TKR in the U.S., 2005-2030

Figure 6.20: Hip Replacement Surgery in OECD Countries, 2009

Figure 6.21: Knee Replacement Surgeries in OECD Countries, 2009

Figure 6.22: U.S. Hip Replacement Market, 2012-2019

Figure 6.23: U.S. Knee Replacement Market, 2012-2019

Figure 6.24: Global Shoulder Replacement Market, 2012-2019

Figure 6.25: Global Market for Hemodialysis, 2012-2019

Figure 6.26: Percent Global Operators of Dialysis Clinics by Country, 2011

Figure 6.27: Global Leaders in Dialysis Products

Figure 6.28: Global Hemodialysis Products Market by Vendor, 2011

Figure 6.29: Global Leaders in Peritoneal Dialysis Products Market, 2011

Figure 6.30: Global Market for Cancer Therapeutics, 2012-2019

Figure 7.1: Estimated Global Market for Coagulation Testing, 2012-2019

Figure 7.2: Anticoagulant Market Segments

Figure 7.3: Mechanism of Action of Warfarin

Figure 7.4: Global Market for Warfarin, 2011-2016

Figure 7.5: Global Market for Factor Xa Inhibitors, 2012-2019

Figure 7.6: Global Market for Rivaroxaban, 2012-2019

Figure 7.7: U.S. Market for Xarelto, 2012-2019

Figure 7.8: Estimated U.S. Market Share of New Anticoagulants in 2019

Figure 7.9: Binding Sites of Univalent and Bivalent DTIs

Figure 7.10: Global Market for Direct Thrombin Inhibitors, 2012-2019

Figure 7.11: Global Market for Pradaxa (Dabigatran), 2012-2019

Figure 7.12: Mechanism of Thrombin Inhibition

Figure 7.13: Mechanism of Action of Indirect Thrombin Inhibitors

Figure 7.14: Global Market for Unfractionated Heparin (UFH), 2012-2019

Figure 7.15: Global Market for LMWHs, 2012-2019

Figure 7.16: Distribution of LMWH Sales per Indication

Figure 7.17: Global Market for Lovenox (Enoxaparin), 2012-2019

Figure 7.18: Sales of Arixtra, 2005-2009

Figure 7.19: U.S. Sales of Angiomax, 2001-2010

Figure 7.20: Global Market for Venous Thromboembolic Drugs, 2012-2019

Figure 7.21: Global Market for Direct Thrombin Inhibitors, 2012-2019

Figure 7.22: Overall Global Market for Anticoagulants, 2012-2019

Figure 7.23: Global Market Share of Anticoagulants by Type, 2011

Figure 7.24: U.S. Market for Anticoagulants, 2012-2019

Figure 8.1: Global Market for Antiplatelets, 2012-2019

Figure 8.2: The Declining Market for Plavix, 2012-2015

Figure 8.3: Market for Effient (Prasugrel), 2012-2019

Figure 8.4: Market for Pletal, 2012-2019

Figure 8.5: Market for Activase (Alteplase), 2012-2019

Figure 8.6: Market for Aggrenox, 2012-2019

Figure 8.7: Market for CardioAspirin, 2012-2019

Figure 8.8: Market for Opalmon (Limaprost), 2012-2019

Figure 8.9: Market for Integrilin, 2012-2019

Figure 8.10: Market for ReoPro, 2012-2019

Figure 8.11: Estimated Market for Diagnostic Assays of Platelet Function, 2013-2018

Figure 10.1: Anti-Thrombotics Prescribed for Stroke Prevention in Asia-Pacific, 2012

Figure 10.2: Antiplatelets Prescribed for Stroke Prevention in Asia-Pacific, 2012

Figure 10.3: Antithrombotic Strategy According to CHADS2 Score, 2012

Figure 10.4: Antithrombotic Strategy for Patients with No Risk Factors (CHADS2=0), 2012

Figure 10.5: Antithrombotic Strategy for Patients with 1 Risk Factor (CHADS2=1), 2012

Figure 10.6: Antithrombotic Strategy for Patients with (CADS2=2) Score 2, 2012

Figure 10.7: Adjustment of INR According to Age

Figure 10.8: Antithrombotic Treatment for Paroxysmal vs. Persistent AF

Figure 10.9: Oral Anticoagulation during Tooth Extraction

Figure 10.10: Oral Anticoagulation during Endoscopy or General Surgery

Figure 10.11: Oral Anticoagulation during Cardioversion for Persistent AF

Figure 10.12: Awareness Levels about New Anticoagulants

Figure 10.13: Awareness about Dabigatran

Figure 10.14: Top Three Reasons for Prescribing Dabigatran in Place of Warfarin

Figure 11.1: Boehringer’s Pipeline (84 Products in Development)

Figure 11.2: The 3D Structure of Dabigatran in Complex with Thrombin

Figure 11.3: Non-CABC-Related TIMI Major or Minor Bleeding Events

Figure 11.4: Time to First Event of CV Death, MI or Stroke (TRITON-TIMI 38)

Figure A1.1: Transesophageal Echocardiogram Showing Thrombus in the Left Atrial

Appendage

INDEX OF TABLES

Table 2.1: Limitations and Consequences of Vitamin K Antagonists

Table 2.2: Pharmacokinetics of Injectable Anticoagulants

Table 2.3: Marketed and Registered Drugs for Anticoagulation and Related Disorders

Table 2.4: Desired Attributes of Newly Developed Anticoagulants

Table 2.5: Comparison of New Anticoagulants

Table 3.1: Examples of Drugs that Interact with Warfarin

Table 3.2: Vitamin K Content of Selected Vegetables

Table 3.3: Weekly Requirements of Vegetables Based on Age and Gender

Table 3.4: Vitamin K Content of Commonly Used Oils

Table 3.5: Vitamin K Content in the Oil of Fast and Processed Foods

Table 3.6: Vitamin K Content in Nutritional Supplements per 8 OZ

Table 3.7: Mean Dabigatran Plasma Concentration and the 25th-75th Percentiles

Table 3.8: Discontinuation Rules before Surgical Procedures

Table 3.9: Strengths and Weaknesses of Dabigatran Compared with Others

Table 3.10: Bleeding Events in ROCKET AF Trial

Table 3.11: Bleeding Events in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD)

Table 3.12: Other Adverse Reactions Reported in RECORD 1-3 Studies

Table 3.13: Clinical Outcomes of EINSTEIN PE

Table 3.14: Primary Composite Endpoint Results in ROCKET AF Study

Table 3.15: Key Efficacy Analysis Results from RECORD Trial

Table 3.16: Phase III AF Trials

Table 3.17: Drugs in Development for Anticoagulation and Related Disorders

Table 3.18: Comparison of Oral Anticoagulants

Table 3.19: Pharmacokinetic Parameters after Five Days of 1.5 mg/kg SC Once Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations

Table 3.20: Pharmacokinetic Parameters of Fondaparinux and Other Anticoagulants

Table 3.21: Composition of 20,000 Anti-Xa IU/mL Innohep

Table 3.22: Comparison of Characteristics of AVE5026, Idrabiotaparinux, Otamixaban and RB006

Table 4.1: Comparison of Top Five Antiplatelets

Table 4.2: Estimated Yearly Incidence of Bleeding with Antiplatelets

Table 4.3: Summary of Evidence for Antiplatelets

Table 4.4: Cost of Antiplatelets

Table 4.5: Information on Ticagrelor

Table 4.6: Product Information on Clopidogrel

Table 4.7: CURE Incidence of Bleeding Complications (% Patients)

Table 4.8: Incidence of Bleeding Event in COMMIT (% Patients)

Table 5.1: Influence of Anticoagulants on Routine Coagulation Assays

Table 5.2: Influence of Anticoagulants on Thrombophilia Assays

Table 6.1: ACC/AHS Recommendations for Antiplatelet Therapy in Patients with NSTEMI or UA

Table 6.2: Dosing of LMWH, Fondaparinux and Bivalirudin in Patients with NSTEMI or UA

Table 6.3: ACC/AHA Recommendations for Anticoagulants Therapy in Patients with NSTEMI or UA

Table 6.4: Antiplatelet Therapy in Patients with STEMI

Table 6.5: Anticoagulants Therapy in Patients with STEMI Who Receive Fibrinolytic Therapy

Table 6.6: Anticoagulants Therapy in Patients with STEMI Who Undergo Primary PCI

Table 6.7: ACCP Recommendations for Thromboprophylactic Strategy Based on Risk for VTE

Table 6.8: Anticoagulants Treatments for VTE

Table 6.9: Projections of Crude Cardiovascular Disease Prevalence, 2010-2030

Table 6.10: Projected Direct Medical Costs for Cardiovascular Diseases, 2010-2030

Table 6.11: Hamilton Score

Table 6.12: Modified Wells Score

Table 6.13: Low Molecular Weight Heparin or Pentasaccharide Indications for VTE Treatment

Table 6.14: Drugs to Prevent Thromboembolism after Hip Fracture

Table 6.15: Complete Blood Count Components

Table 7.1: Oral Anticoagulants Utilization and Cost per Claim

Table 7.2: Oral Anticoagulation Utilization by Age Band, 2011

Table 7.3: Users New to Anticoagulation Therapy and Switch Rate, 2011

Table 7.4: Alternatives to Warfarin

Table 7.5: FDA-Approved Direct Thrombin Inhibitors

Table 7.6: FDA-Approved Parenteral Anticoagulants

Table 7.7: Pharmacokinetics of Parenteral Anticoagulants

Table 7.8: Adverse Effects of Parenteral Anticoagulants

Table 7.9: Available Forms of Parenteral Anticoagulants

Table 7.10: Characteristics of Available LMWH

Table 7.11: Risk Factors for Venous Thromboembolism

Table 7.12: Anti-Thrombotic Agents Market, 2012 and 2019

Table 7.13: Partial List of Anticoagulants in Development

Table 8.1: Comparison of Antiplatelets

Table 8.2: History of Prasugrel

Table 9.1: Selected Sanofi’s Agreements for Antithrombotics

Table 9.2: Selected Daiichi Sankyo’s Agreements for Anti-Thrombotics

Table 9.3: Agreements for Integrilin

Table 9.4: Agreements for Aggrastat

Table 9.5: Notable High-Value Deals for Anti-Thrombotics

Table 11.1: Cipla’s Anticoagulant and Antithrombotic Products

Table 11.2: Dosage and Administration of Fragmin

Table 11.3: Patients with Outcome Events in TRITON-TIMI 38

Table 11.4: Medication Information for Tinzaparin

Table 11.5: Product Pipeline from Portola

Table 11.6: Dosage and Administration of Lovenox

Table A1.1: Risk Factors for Thromboembolism and Latest Guideline Management Recommendations

Table A1.2: Comparison of the Three Studies of New Anticoagulants for Atrial Fibrillation

To order this report:

New Oral Anticoagulants Markets

Contact: Shauna

800.298.5699

customerservice(at)marketresearch(dot)com

About TriMark Publications

TriMark Publications is a premium market-research and publishing company providing original reports in the biotechnology, medical device, diagnostic and healthcare segments. Clients benefit from an expert, objective source for their research needs, saving time and resources.

TriMark Publications' reports are wide-ranging research publications that explore development activity, recent advances, and emerging trends in health care markets. In addition to our in-house proprietary database, the TriMark staff seeks out experts in the field, conducting extensive secondary research, and develops the findings into a cohesive, well-documented written analysis. Our specialty is constant staff review of reports to continually add and revise so that each report is absolutely up to date.

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world’s most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com’s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Cindy Frei at 240.747.3014 or visit http://www.marketresearch.com

Follow us on Facebook http://www.facebook.com/marketresearchdotcom

Follow us on Twitter http://www.twitter.com/marketresearch_

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10858382.htm


Source: prweb